Search - tctmd.com

Displaying 601 - 620 of 1240

Sort: Relevancy | Date

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

January 31, 2019

Top Stories in Cardiology: January 2019

Podcast Heart Sounds

Top Stories in Cardiology: January 2019

January 30, 2019

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

January 08, 2019

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

News Daily News

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

Michael O'Riordan

January 03, 2019

Top News in Coronary Artery Disease: 2018

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

US and European DAPT Guidelines More Alike Than Different, Say Experts

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

November 23, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Updateon PCS K-9 Inhibition

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

October 29, 2018

Patients With Schizophrenia Reap Gains From CV Meds After MI

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

October 24, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.